Background <p>B-cell maturation antigen (BCMA) is the main target for chimeric antigen receptor (CAR)-T cells in multiple myeloma (MM), demonstrating promising outcomes. However, unlike what happens with CART19 in lymphoblastic leukemia and non-Hodgkin's lymphoma, a high proportion of patients will relapse after CAR-T BCMA therapy due to insufficient antigen expression, low CAR-T cell persistence and/or T-cell exhaustion. In other B…
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain
Journal for ImmunoTherapy of Cancer | | Cardus, O., Mane Pujol, J., de Daniel, A., Moreno, D. F., Oliveira, T. G. M., Battram, A. M., Salsench, S. V., Perez-Amill, L., Llobregat, H., Carpio Marmol, J., Martin-Antonio, B., Oliver-Caldes, A., Munarriz, D., Juan, M., Urbano-Ispizua, A., Rodriguez-Lobato, L. G., Fernandez de Larrea, C.
Topics: blood-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer